EUCTR2009-011838-10-IT进行中（未招募）不适用
PHASE II STUDY ON TREATMENT WITH VELCADE, DEXAMETHASONE AND FOTEMUSTINE IN PATIENTS AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA - B-MUD
OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2009年4月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Documented relapsed or progressive disease after al least one previous therapy; age > 18; Performance status score > 60%; MM documented in serum or urine; absence of severe disease or concomitant neoplasia; Negative HIV test; Negative pregnancy test; Laboratory values within the protocol limits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy or breast-feeding; neuropathy >= grade 2 NCI; concomitant biological therapy, immunotherapy or other experimental drugs in the previous 21 days; plasmapheresis in the previous 30 days; Major surgery in the previous 30 days.
研究者
相似试验
进行中（未招募）
不适用
A PHASE III STUDY OF VELCADE (BORTEZOMIB)-DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB)-THALIDOMIDE-DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA - VD versus VTDPATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, UNDER THE AGE OF 66, CANDIDATE FOR AUTOLOGOUS STEM CELL TRANSPLANTATIONMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2007-005204-40-BEIntergroupe Francophone du Myélome200
进行中（未招募）
不适用
A PHASE III STUDY OF VELCADE (BORTEZOMIB) DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA. - VD vesus VTDPATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, UNDER THE AGE OF 66, CANDIDATE FOR AUTOLOGOUS STEM CELL TRANSPLANTATIONMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2007-005204-40-FRIntergroupe Francophone du Myélome200
已完成
1 期
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma PatientsMultiple MyelomaNCT00507442Millennium Pharmaceuticals, Inc.158
进行中（未招募）
不适用
Phase II Study of VELCADETM in patientswith extranodal marginal zone B-cell lymphoma ofMALT-type pretreated with more than one prior systemictherapy regimen (X05142)lymphoma of MALTEUCTR2004-004596-11-ESInternational Extranodal Lymphoma Study Group35
进行中（未招募）
1 期
Phase II Study of VELCADETM in patientswith extranodal marginal zone B-cell lymphoma ofMALT-type pretreated with one prior systemic therapyregimen (X05142)EUCTR2004-004594-29-ESInternational Extranodal Lymphoma Study Group35